6:25 PM
 | 
Jan 23, 2013
 |  BC Extra  |  Company News

Celsion grants ThermoDox option to Zhejiang Hisun

Celsion Corp. (NASDAQ:CLSN) granted Zhejiang Hisun Pharmaceutical Co. Ltd. (Shanghai:600267) rights to develop liver cancer compound ThermoDox in China and its territories, including Hong Kong and Macau. Celsion will receive $5 million up front...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >